Clinical Trials Browser

Phase 2 × OTHER × XRP6258 × Clear all

NCT02703623 2026-03-06

Abiraterone Acetate, Prednisone, and Apalutamide With or Without Ipilimumab or Cabazitaxel and Carboplatin in Treating Patients With Metastatic Castration-Resistant Prostate Cancer

Phase 2 Active not recruiting

Prostatic Neoplasms

NCT04592237 2025-12-23

Cabazitaxel, Carboplatin, and Cetrelimab Followed by Niraparib With or Without Cetrelimab for the Treatment of Aggressive Variant Metastatic Prostate Cancer

Phase 2 Active not recruiting

Prostatic Neoplasms

NCT02844582 2021-01-25

Cabazitaxel and Prednisone in Treating Patients With Metastatic Hormone-Resistant Prostate Cancer

Phase 2 Terminated

2 enrolled 5 charts

Hormone-Resistant Prostate Cancer

NCT04622761 2021-01-05

CHROME

Phase 2 Not yet recruiting

Prostatic Neoplasms

NCT02166658 2018-01-23

CaBaMet

Phase 2 Terminated

BreastCNSThoracic

Brain Neoplasms, Breast Neoplasms, Lung Neoplasms, Neoplasm Metastasis, Recurrence

NCT01693549 2017-08-01

Study of Cabazitaxel in Patients With Metastatic Breast Cancer Previously Treated With Taxanes

Phase 2 Completed

Breast Neoplasms

NCT01934894 2017-07-02

Cabazitaxel Plus Lapatinib as Therapy for HER2-Positive Metastatic Breast Cancer Patients With Intracranial Metastases

Phase 2 Terminated

11 enrolled 7 charts

Metastatic Breast Cancer With Intracranial Metastases

NCT01469338 2014-11-24

Cabazitaxel Plus Prednisone With Octreotide For Castration-Resistant Prostate Cancer (CRPC) Previously Treated With Docetaxel

Phase 2 Terminated

Diarrhea, Prostatic Neoplasms

NCT01750866 2013-10-16

Cabazitaxel in Men 75 Years of Age or Older With Castration-Resistant Prostate Cancer

Phase 2 Withdrawn

Castrate-resistant Metastatic Prostate Cancer